Copy Link Print Information

Zanamivir hydrate(5:1)

17 Cited Publications
Customer Review

Based on 17 publication(s) in Google Scholar

Zanamivir hydrate (5:1) is the hydrate of Zanamivir. Zanamivir is an influenza viral neuraminidase inhibitor with IC50 values of 0.95 nM and 2.7 nM for influenza A and B, respectively.

For research use only. We do not sell to patients.

  • CAS No.: 171094-50-1
  • Formula: C12H20.4N4O7.2
  • Molecular Weight:335.91
  • Storage:

    Please store the product under the recommended conditions in the Certificate of Analysis.

  • Zanamivir hydrate(5:1) Chemical Structure
    Zanamivir hydrate(5:1) Chemical Structure
  • Experimental Validation Results for Zanamivir hydrate(5:1)
  • Experimental Validation Results for Zanamivir hydrate(5:1)
  • Experimental Validation Results for Zanamivir hydrate(5:1)
  • Experimental Validation Results for Zanamivir hydrate(5:1)
  • Experimental Validation Results for Zanamivir hydrate(5:1)
CAS No.: 171094-50-1
Size
Price
Stock
Quantity
Amount: USD 0.00
Please select quantity
or
or

* Please select Quantity before adding items.

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Data Download
Other Forms of Zanamivir hydrate(5:1):

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
Find Your Local Distributor Your local distributor: Hycultec GmbHHycultec
  • Biological Activity
  • Chemical Information
  • Protocols
  • Purity & Documentation
  • References
  • Help & FAQs
Top Publications Citing

Use of MCE Products

Publications Citing Use of MedChemExpress (MCE) Zanamivir hydrate(5:1)

More
Customer Validation & Images
WBRT-PCRCell Proliferation/Viability AssayMicrobiological Assay
  • Microbiological Assay
  • WB
  • Cell Proliferation/Viability Assay
  • RT-PCR
  • Cell Proliferation/Viability Assay

All Antibiotic Isoforms

More

Keywords

MOQ
Minimum order quantity
100 mg

Get Quote In-stock

Other size
Get Quote
Please select quantity
Amount: USD 0.00
Sign in to MedChemExpress Sign In
Register
Sign in to MedChemExpress
Register New Account

At least 6 characters

Personalize your experience, you are currently not signed in. For a better experience, please create an online profile, you can:

Obtain points redemption prizes
Check out faster
Add multiple shipping locations
View orders
Assay Types
  • Zanamivir hydrate(5:1) Chemical Structure
    Zanamivir hydrate(5:1) Chemical Structure
    1/16
  • 1/16

    Zanamivir hydrate(5:1) purchased from MedChemExpress. Usage Cited in: Emerg Microbes Infect. 2025 Dec;14(1):2564308. [Abstract]

    Customer Validation
     Compound susceptibility profiles of Zanamivir was assessed using a viral yield reduction assay in MDCK cells. Cells were infected with IDV and IAV (MOI = 0.1), followed by removal of the virus inoculum and treatment with serially diluted compounds. Supernatants were collected at designated timepoints post-infection for TCID50 titration. Antiviral activity (%) was calculated relative to virus-free and drug-free controls.

  • 1/16

    Zanamivir hydrate(5:1) purchased from MedChemExpress. Usage Cited in: PLoS Pathog. 2024 Feb 14;20(2):e1011981. [Abstract]

    Customer Validation
     Western blotting analysis of LAMP1 and LAMP2 deglycosylation and degradation in HeLa cells transfected with plasmid expressing HN protein and treated with Peramivir (30 μg/mL) or Zanamivir (20 μg/mL; 24-48 h) at the indicated time points post-transfection. The results demonstrated that treatment with either Peramivir or Zanamivir significantly inhibited the deglycosylation and degradation of LAMP1 and LAMP2 following the transfection of the HN protein.

  • 1/16

    Zanamivir hydrate(5:1) purchased from MedChemExpress. Usage Cited in: Viruses. 2024 Sep 14;16(9):1467. [Abstract]

    Customer Validation
     Inhibitory effect of baloxavir in combination with NAIs in cells infected with H1N1-PR8-I38T mutant strain. The antiviral activity of baloxavir + NAIs was evaluated against H1N1-PR8-I38T in MDCK cells. Graphs showing the antiviral activity of baloxavir in combination with Zanamivir (3 days).

  • 1/16

    Zanamivir hydrate(5:1) purchased from MedChemExpress. Usage Cited in: Signal Transduct Target Ther. 2021 Apr 24;6(1):165. [Abstract]

    Customer Validation
     The preliminary in vitro antiviral activities of oseltamivir at 3 μM, Zanamivir (51 h) at 3 μM, baricitinib at 3.2 μM, olaparib at 3.2 μM, arbidol at 3 μM and 30 μM, and CVL218 at 3 μM and 30 μM, respectively, were detected in Vero E6 cells infected with SARS-CoV-2 at an MOI of 0.05. The viral yield in the cell supernatant was then quantified by qRT-PCR.

  • 1/16

    Zanamivir hydrate(5:1) purchased from MedChemExpress. Usage Cited in: Antimicrob Agents Chemother. 2020 Jun 23;64(7):e00222-20. [Abstract]

    Customer Validation
     Synergetic antiviral effect of compounds 4a in combination with Zanamivir in cells infected with drug-resistant influenza virus. MDCK cells were infected with the ZX/1109 strain in the presence of the indicated concentrations of Zanamivir, and cell viability was evaluated at 3 days postinfection. The synergetic effects of compound 4a and Zanamivir were analyzed by MacSynergy II and shown in a three-dimensional plot. The volumes above and below the planes represent synergy and antagonism, respectively.

  • Zanamivir hydrate(5:1)